This Could Be the Next Biopharma IPO

Several major hedge funds are poised to benefit if Acelyrin’s offering is successful.

Toru Hanai/Bloomberg

Toru Hanai/Bloomberg

Another fledgling biopharma company is looking to test the IPO market — and several well-known hedge funds hope to reap the benefits.

Acelyrin, a late-stage clinical biopharma company focused on “transformative medicines,” recently filed plans to go public. The company has not yet disclosed how many shares it plans to offer or the price target it is seeking.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.